Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.49 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 11/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.46 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29405721 | 1.00 | CYP19A1 (0.49) | CYP19A1DGAT1ITGB3ITGA2BCYP26A1 | |
| SCHEMBL9638064 | 0.87 | CYP19A1 (0.64) | CYP19A1DGAT1ITGB3ITGA2BCYP26A1 | |
| SCHEMBL6067801 | 0.85 | METAP1 (0.46) | CYP19A1DGAT1ITGB3ITGA2BFFAR1 | |
| SCHEMBL20255760 | 0.84 | CYP19A1 (0.43) | CYP19A1DGAT1CYP26A1TDP1L3MBTL1 | |
| SCHEMBL10662181 | 0.83 | DGAT1 (0.51) | CYP19A1DGAT1ITGB3ITGA2BCYP26A1 | |
| SCHEMBL18322010 | 0.82 | HSD17B1 (0.42) | CYP19A1CYP26A1 | |
| SCHEMBL28601267 | 0.81 | FFAR1 (0.50) | FFAR1 | |
| SCHEMBL28601201 | 0.81 | FFAR1 (0.50) | FFAR1 | |
| SCHEMBL10686519 | 0.80 | CYP19A1 (0.59) | CYP19A1CYP26A1TDP1L3MBTL1 | |
| SCHEMBL29679345 | 0.80 | CYP19A1 (0.59) | CYP19A1CYP26A1TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3766878-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-03-16 | — | — | EP | disclosed |
| CN-108137557-B | Nrf2 modulators | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-09-07 | — | — | CN | disclosed |
| EP-3766878-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-01-20 | — | — | EP | disclosed |
| EP-3307729-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-09-02 | — | — | EP | disclosed |
| US-20190224212-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2019-07-25 | — | — | US | disclosed |
| US-20190224212-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2019-07-25 | — | — | US | disclosed |
| US-10272095-B2 | NRF2 regulators | GlaxoSmithKline Intellectual Propert Development Limited (GB) | 2019-04-30 | — | — | US | disclosed |
| US-10272095-B2 | NRF2 regulators | GlaxoSmithKline Intellectual Propert Development Limited (GB) | 2019-04-30 | — | — | US | disclosed |
| US-20180169110-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2018-06-21 | — | — | US | disclosed |
| WO-2018104766-A1 | 3-(2,3-DIHYDRO-1H-INDEN-5-YL)PROPANOIC ACID DERIVATIVES AND THEIR USE AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-14 | — | — | WO | disclosed |
| EP-3307729-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-04-18 | — | — | EP | disclosed |
| WO-2016203401-A1 | NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10272095-B2 | NRF2 regulators | NFE2L2, KEAP1, NQO1 | CYP19A1 971/4885DGAT1 562/4885ITGB3 3651/4885 |
| US-20190224212-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | CYP19A1 971/4885DGAT1 562/4885ITGB3 3651/4885 |
| US-20180169110-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | CYP19A1 971/4885DGAT1 562/4885ITGB3 3651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.